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Background: Conventional therapy for patients with maple syrup urine disease (MSUD) entails restriction of protein
intake to maintain acceptable levels of the branched chain amino acid, leucine (LEU), monitored in blood. However,
no data exists on the correlation between brain and blood LEU with protein restriction, and whether correction in
blood is reflected in brain.
Methods: To address this question, we fed intermediate MSUD mice diets of 19% (standard) and 6% protein, with
collection of sera (SE), striata (STR), cerebellum (CE) and cortex (CTX) for quantitative amino acid analyses.
Results: LEU and valine (VAL) levels in all brain regions improved on average 28% when shifting from 19% to 6%
protein, whereas the same improvements in SE were on average 60%. Isoleucine (ILE) in brain regions did not
improve, while the SE level improved 24% with low-protein consumption. Blood-branched chain amino acids (LEU,
ILE, and VAL in sera (SE)) were 362-434 μM, consistent with human values considered within control. Nonetheless,
numerous amino acids in brain regions remained abnormal despite protein restriction, including glutamine (GLN),
aspartate (ASP), glutamate (GLU), gamma-aminobutyric acid (GABA), asparagine (ASN), citrulline (CIT) and serine
(SER). To assess the specificity of these anomalies, we piloted preliminary studies in hyperphenylalaninemic mice,
modeling another large neutral aminoacidopathy. Employing an identical dietary regimen, we found remarkably
consistent abnormalities in GLN, ASP, and GLU.
Conclusions: Our results suggest that blood amino acid analysis may be a poor surrogate for assessing the
outcomes of protein restriction in the large neutral amino acidopathies, and further indicate that chronic
neurotransmitter disruptions (GLU, GABA, ASP) may contribute to long-term neurocognitive dysfunction in these
disorders.
Keywords: Maple syrup urine disease (MSUD), Branched-chain keto-acid dehydrogenase (BCKDH) complex, Mouse
model, Large neutral amino acid transporter (LAT-1), Branched-chain amino acids (BCAAs), Phenylketonuria (PKU),
Large neutral aminoacidopathies, Dietary protein restrictionBackground
Maple syrup urine disease (MSUD; branched chain ketoa-
cid dehydrogenase (BCKDH) deficiency) and phenylketon-
uria (PKU) comprise the large neutral aminoacidopathies.
Untreated MSUD results in accumulation of the branched-
chain amino acids (BCAAs) leucine (LEU), valine (VAL)
and isoleucine (ILE) [1-4]. Additionally, induction of* Correspondence: mike.gibson@wsu.edu
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(KIV, from VAL), all of which can freely traverse the
blood–brain barrier (BBB) and transaminate to yield
the corresponding BCAAs [5]. Treatment of MSUD
requires strict protein restriction combined with BCAA
supplementation to levels compatible with adequate
development and growth. Although dietary intervention
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challenges that include maintenance and adherence to
diet, and mounting evidence for long-term deficits in
neurocognition despite acceptable metabolic control
determined in blood [6-16]. Additionally, over restric-
tion of dietary amino acid intake may have untoward
consequences. The preceding discussion suggests that
while prudent, dietary treatment alone for MSUD may
be suboptimal.
The pathophysiology of MSUD has been extensively
reviewed [17]. Episodic increases in blood BCAAs occur
when muscle degrades protein in response to physio-
logical stress [18-20], also increasing the level of corre-
sponding BCKAs. Increased muscle BCKAs induces
reversal of cytosolic transaminases and depletes tissue
levels of other amino acid nitrogen donors. As LEU exits
muscle and other tissues via the large neutral amino acid
transporter (LAT-2) [21], heteroexchange mechanisms
stoichiometrically drive import of other amino acids and
increase the relative LEU blood concentration. At the
BBB, elevated BCAAs may saturate the LAT-1 (see below)
transporter and block uptake of other large neutral amino
acids (LNAA; including phenylalanine (PHE), tyrosine
(TYR), methionine (MET); tryptophan (TRP); and histi-
dine (HIS)). Increased blood BCKAs enter the brain via
the monocarboxylate transporter (MCT) and reverse flux
through cerebral transaminases, depleting brain glutamate
(GLU), glutamine (GLN) and gamma-aminobutyric acid
(GABA) (among others), while enhancing production of
LEU and α-ketoglutarate [5,22-25]. These disruptions in
brain amino acid homeostasis may also be accompanied
by disruptions of oxidative phosphorylation, elevated cere-
bral lactate level and oxidative damage [20,26].
As noted above, LNAAs cross the BBB on the LAT-1
transporter, and accumulation of offending amino acids
such as the BCAAs in MSUD can result in exclusion of
other LNAAs from the brain, although this has not been
rigorously evaluated in either patients or an animal model
of MSUD. Despite the specificity of the LAT-1 for LNAAs,
most brain amino acid transport systems display broad
overlap in the amino acids transported [3,4,27,28]. Here,
we have employed a murine model of MSUD to address
the question of whether control of BCAA level, as moni-
tored in blood, is reflected by similar correction in the
brain. Several novel therapeutic approaches to PKU have
emerged recently [29], yet with the exceptions of phenyl-
butyrate administration (which selectively lowers circulat-
ing BCAAs) [30] or orthotopic liver transplantation for
the most severe forms of MSUD [8,15,31,32], few thera-
peutic advances have emerged in MSUD. The current re-
port addresses our hypothesis, and for the first time
verifies in a murine model of MSUD that assessment of
metabolic control using blood studies is a poor surrogate
for disturbances of amino acid homeostasis in the brain.Methods
Animal subjects
The intermediate MSUD murine model (imsud mice) has
been described, and manifests ~ 6% of residual BCKDH
enzyme function [1,2,33,34]. Animal subjects were geno-
typed by PCR amplification. Subjects of both genders were
employed, ages 10–20 days of life. Subjects were allowed
ad libitum access to chow and water throughout experi-
mentation. All animal experimentation was performed
with IACUC approval (ASAF 4232–007).
Diets employed
We performed pilot studies with the Teklad TD.90016
diet (6.9% casein = 6% protein; low protein) since it has
been employed previously for maternal protein restric-
tion in rodents [35]. In the latter studies, the induction
of serine-metabolizing enzymes was characterized in mice
receiving 2, 6 and 18% protein. Based upon empiric consid-
erations, we felt that 2% protein would be too stringent in
imsud mice and lead to catabolic crisis. Teklad custom
diets are isocaloric and balanced for nitrogen level. The
corresponding Teklad TD.91353 diet (19% protein) was
used as control diet. Animals were on diet for 8–18 days
prior to sacrifice. Power analyses indicated that n = 6
subjects of each genotype (imsud+/+ and imsud−/−) would
be sufficient to obtain statistically significant outcomes. For
brain region analyses (see below), we frequently had n = 5-
6 subjects per diet and genotype, but the smaller size of
mutant subjects often led to insufficient blood for analyt-
ical studies, thereby leading to smaller n values for sera
(SE) and enhanced data variability. At study conclusion,
subjects per genotype were n = 3-7 for SE and n = 4-8 for
brain.
Tissue harvesting and analytical methodology
At appropriate time points, animal subjects were eutha-
nized, and blood collected by cardiac puncture. The brain
cavity was rapidly accessed on an ice-cold glass plate, with
parietal cortex (CTX), striata (STR), and cerebellum (CB)
rapidly excised. Harvested tissues and sera following centri-
fugation were stored at – 80°C until analyses. LNAAs and
other amino acids were determined with an ultraperfor-
mance liquid chromatography (UPLC) MassTrak amino
acid system as previously described [36]. All values in SE
are presented in units of μmol/L, wherease all values in
brain regions are presented in units of nmol/gr tissue.
Statistical analyses
In prior studies, we had observed depletion of GLU,
GLN, ASP, serine (SER), alanine (ALA) and GABA, with
elevated glycine (GLY) in brain of imsud mice. However,
those studies were performed in whole brain [1,2,33,34],
potentially leading to artifact from mixing of regions
with high vs. low metabolite levels. In the current study
Figure 1 Branched chain amino acids in sera (SE), cerebellum (CB), striata (STR) and cortex (CTX) as a function of protein intake (6 or 19%)
and genotype (w, wild-type; m, mutant). Two-way ANOVA (parameters: protein intake, tissue), p = ns for tissue and interaction, p < 0.05 for protein
intake. Two-tailed t-test, p < 0.05 for all mutant vs. wild-type (not shown).
Figure 2 Alloisoleucine levels (see Figure 1 for details). Two-way
ANOVA, p < 0.05 for protein intake, p = ns for tissue and interaction.
Two-tailed t-test, p = ns between mutant and wild-type as a function of
protein intake.
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no insight whether to expect brain regional amino acids
to be constant or different. Thus, we initially employed a
two-way ANOVA to assess correlations between brain
region and protein intake, and interaction of these pa-
rameters, accompanied by a Holm-Sidak’s multiple com-
parisons test. Our primary statistical analyses employed
a two-tailed t test within genotype as a function of pro-
tein consumption. Both statistical evaluations are pre-
sented in all figure legends. Comparisons of amino acid
concentrations between blood and brain assumed a
density of brain tissue of ~1 g/ml [37].
Results
For imsud mice, all BCAAs were significantly increased
in comparison to littermate controls, verifying the utility
of the model (Figure 1). With decreased protein con-
sumption, LEU in mutant SE decreased from 1072
(504) (standard deviation shown in parenthesis after
mean) to 436 (107) μmol/L, while the same decreases
in mutant were 1026 (444) to 723 (415) in CB, 1147
(535) to 853 (648) in STR and 1017 (516) to 755
(452) in CTX (brain regions: nmol/gr tissue). ILE
changes in mutant mice with decreased protein were
488 (115) to 362 (41) μmol/L in SE, 555 (84) to 585
(226) in CB, 625 (132) to 687 (349) in SE and 583
(126) to 636 (235) in cortex (nmol/gr tissue). For
VAL, comparable changes were 1007 (441) to 434
(71) μmol/L in SE, 950 (347) to 651 (288) in CB,
1071 (421) to 758 (453) in STR and 894 (448) to 661
(351) in CTX (nmol/gr tissue).
Within tissues (SE, CB, STR and CTX), there was no
significant improvement in BCAAs with lowered protein
intake, although the trend in SE BCAAs approached sig-
nificance (t-test, 2-tailed, p = 0.074-0.125 vs. CB, STR and
CTX, p = 0.210-0.789), but variation in SDs (occasional
low SE quantity for selected animals) was problematic.
Alloisoleucine (ALLO, a pathognomonic biomarker for
MSUD) showed similar trends (Figure 2). The changes forALLO in mutants with decreased protein consump-
tion were 39 (22) to 12 (3) μmol/L in SE, 66 (37) to
37 (24) in CB, 75 (44) to 44 (31) in STR, and 41 (29)
to 27 (15) in CTX (brain values, nmol/gr protein).
As expected, ALLO was undetectable in wild-type
mice with either diet. There was no significant differ-
ence in any tissue with decreased protein intake for
ALLO in mutant mice.
We then turned our attention to the other LNAAs
(MET, PHE, TYR and TRP) in the same regions
(Figure 3). For TYR, changes for mutant mice with
decreased protein intake were 94 (19) to 134 (10)
μmol/L in SE, 98 (13) to 143 (44) in CB, 57 (n = 2)-
92 (26) in striata and 102 (17) to 139 (46) in CTX
(brain, nmol/gr tissue). For TRP, the same values for
mutant were 49 (5) to 57 (12) μmol/L in SE, 28 (4)
to 31 (8) in CB, 28 (7) to 32 (10) in STR and 25 (4)
to 26 (9) in CTX. For MET, these values were 77
(16) to 82 (27) μmol/L in SE, 132 (41) to 93 (29) in
CB, 121 (40) to 113 (28) in STR and 146 (11) to 143
Figure 3 Other large neutral amino acids (tyrosine, tryptophan, methionine, phenylalanine) as a function of protein intake and genotype
(see Figure 1 for details). Two-tailed ANOVA, p < 0.05 for both protein intake, tissue and interaction. Two-tailed t-test (*p < 0.05), comparing M19 and
W19 in CTX and CB (TYR) and STR (TRP). Also, p < 0.05 for TYR in SE (M6 vs M19).
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94 (15) to 86 (19) μmol/L in SE, 104 (13) to 118 (13)
in CB, 99 (17) to 124 (41) in STR and 100 (12) to
101 (14) in CTX (nmol/gr tissue).
Elevated BCAA levels had no substantial effect on TRP,
MET and PHE levels in any brain region, although SE
TYR was improved (increased in mutant mice; Figure 3)
with decreased protein consumption (without a corre-
sponding correction in brain regions). This finding lends
credence to the hypothesis that correction of blood amino
acid content may not reflect corresponding corrections in
brain. Conversely, compared to control mice receiving
identical diet, levels of TYR or TRP were depleted in CB,
STR and CTX with high protein intake, but these deple-
tions were not consistent across different brain regions
(Figure 3).
We next surveyed all remaining physiological amino
acids across brain regions, and observed significant abnor-
malities in GLN, ASP, GLU, GABA, ASN (asparagine);
CIT (citrulline), SER and ALA (Figures 4, 5 and 6). For
comparison purposes, concentrations for GLN, ASP andFigure 4 Neurotransmitter amino acids (glutamine, aspartate, glutam
Figure 1 Legend). Two-way ANOVA, p < 0.05 for tissue, protein intake and
under both protein intake regimens.GLU are not depicted for SE because of the much higher
brain levels, which would graphically dwarf SE values, and
GABA is not quantifiable in SE. Changes in GLN in mu-
tant brain regions with decreased protein consump-
tion were 2590 (726) to 3021 (477) in CB, 1575 (516)
to 2342 (503) in STR and 1862 (739) to 2064 (336)
in CTXD (nmol/gr tissue). For ASP, the same changes
with decreased protein were 1818 (303) to 2206 (420)
in CB, 1662 (517) to 1829 (183) in STR and 1808
(420) to 2021 (187) in CTX; for GLU, 4973 (774) to
5045 (1263) in CB, 6238 (1264) to 6554 (407) in STR
and 7019 (1226) to 7246 (134) in CTX; and for
GABA, 1920 (207) to 2317 (378) in CB, 1958 (316) to
2364 (409) in STR and 2595 (171) to 2789 (329) in
CTX (nmol/gr tissue).
With the exception of GABA (which improved with
lower protein intake), GLN, ASP and GLU were not im-
proved with lowered protein consumption (Figure 4).
Conversely, lowered protein intake normalized the level of
ASN in CB and the concentration of CIT in STR and
CTX, while both amino acids were significantly increasedate and GABA) as a function of protein intake and tissue (see
interaction. Two-tailed t-test, *p < 0.05 for all mutant vs. wild-type
Figure 5 Asparagine and citrulline level as a function of protein intake and tissue. Two-way ANOVA, p < 0.05 for protein intake and interaction,
p = ns for tissue. Two-tailed t-test, *p < 0.05 between genotype with identical protein intake.
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findings were observed for SER and ALA, in which cor-
rection with lowered protein consumption was observed
in CB, but not in STR or CTX (Figure 6). Threonine
(THR) is often considered a member of the LNAA sub-
group, but we found no consistent changes in brain re-
gions, with the exception of a single instance in striata
(Figure 7). Conversely, LYS is not considered a LNAA, yet
its values were significantly impacted during high-protein
consumption (Figure 7).
Since concentrations of several amino acids are much
lower in SE vs. brain regions (e.g., Figures 1, 2, and 3),
we did not present them graphically, as noted above. We
observed no significant changes for GLU and GLN in SE
(p > 0.05), yet found brain disruptions that were uncor-
rected with lowered protein intake (Figure 4). Con-
versely, in SE we observed a significant difference for
ASP (19% diet: imsud−/−, 59 ± 17 (n = 5) vs. imsud+/+,
104 ± 21 (n = 7) (p < 0.05), which corrected with 6% diet
(imsud−/−, 78 ± 37 (n = 3) vs. imsud+/+, 136 ± 90 (n = 5)
(p = ns). ASN in SE was within normal limits for imsud
subjects, despite significant alterations in brain. For CIT,
elevations in SE approximated those seen in brain regionsFigure 6 Serine and alanine levels as a function of protein intake and ti
Two-tailed t-test, *p < 0.05 for genotype with identical protein intake.(data not shown). SER levels in SE were not abnormal in
mutant mice (although they were disrupted in brain re-
gions; Figure 6). Conversely, disruptions of ALA levels in
SE mirrored the abnormalities observed in brain (data not
shown). Of interest, abnormalities of LYS in SE mirrored
the disruptions observed in brain (Figure 7), especially in
the instance of high-protein intake, perhaps suggesting
that some portion of LYS is trafficked on the large-neutral
amino acid transporter.
Depletion of brain GLN, GLU and GABA have been
suggested to associate with transamination via accumu-
lated KIC in brain [5]. Accordingly, we predicted that
Pahenu2 mice (representing the large neutral aminoacido-
pathy PKU [3,4]) would have normal GLN, GLU and
GABA since KIC is not elevated in this disorder. To ad-
dress this hypothesis, we developed cohorts of Pahenu2−/−
mice and parallel controls and fed them diets identical to
those given to imsud mice. We first verified the utility of
our PKU model through quantitation of brain PHE
levels, which was significantly increased (and not cor-
rected even with 6% protein intake; Figure 8). Unex-
pectedly, alterations in brain regions for ASP, GLN
and GLU in Pahenu2−/− mirrored those observed inssue. Two-way ANOVA, p < 0.05 for protein intake, tissue and interaction.
Figure 7 Threonine and lysine levels as a function of protein intake and tissue. Two-way ANOVA, p < 0.05 for protein intake, tissue and
interaction. Two-tailed t-test, *p < 0.05 for genotype with identical protein intake.
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mice with decreased protein intake were: GLN: 3675
(381) to 4500 (258) in CB, 1964 (261) to 2308 (208)
in STR and 1557 (280) to 1876 (297) in CTX (nmol/
gr tissue); ASP: 2468 (443) to 2335 (98) in CB, 1758
(293) to 1661 (109) in STR and 2216 (456) to 2044
(306) in CTX; CLU: 6781 (559) to 6833 (320) in CB,
6041 (461) to 5777 (363) in STR and 6427 (810) to
6164 (637) in CTX; GABA: 2152 (279) to 2470 (283)
in CB, 1735 (264) to 1470 (168) in STR and 2304
(233) to 2271 (308) in CTX (all nmol/gr tissue). The
striking similarity in abnormalities between imsud−/−
and Pahenu2−/− mice in different regions of the brain,
as a function of protein intake (Figure 9), suggests
that other factors, in addition to brain keto-acid ac-
cumulation, may be at play in the brains of animals
with large neutral aminoacidopathies, and most likely
in patients as well.Figure 8 Phenylalanine levels as a function of protein intake
and tissue in phenylketonuric mice. Two-way ANOVA, p < 0.05 for
protein intake, tissue and interaction. All values in mutant mice were
significantly increased in comparison to control mice (p < 0.05, two
tailed t-test; not shown on graph).Discussion
The range of means for BCAAs in SE of imsud mice re-
ceiving 6% dietary protein was 362-434 μM (Figure 1),
consistent with the range of LEU for 13 intermediate
MSUD patients under dietary intervention (379 ± 147 μM;
[38]) and 282 ± 277 μM for classical MSUD patients [5]
considered to be under “metabolic control”. Based on
these human data, 6% protein consumption normalized
blood BCAAs, yet we observed significant disruption of
several other amino acids in the brain despite apparent
metabolic control manifested in SE. We hypothesized that
reduced levels of GLN, GLU, GABA and ALA in brain
regions might be partially explained by KIC accumulation
([5]; see Figures 4 and 6; not measured in the current
study), yet similar anomalies in PKU mice argues against
this hypothesis (Figure 9). CIT accumulation in imsud
brain regions likely reflects depletion of ASP, the latter ne-
cessary for condensation with CIT to form argininosucci-
nate within the urea cycle.
The original studies of Pardridge and Oldendorf [39] in
the rat indicated that PHE, TRP, MET, TYR, LEU, ILE,
VAL and HIS were transported into the brain on the
LAT-1, with Km values ranging from~ 25 to 200 μM
(highest affinity, PHE; lowest affinity HIS). Limited data
suggests that THR and LYS may also traffic on LAT-1
[3,4,40,41], yet we found no evidence for disrupted THR
levels. Conversely, we did detect decreased LYS in brain
regions of imsud subjects. LYS would be expected to be
transported predominantly via the B transporter [3], al-
though there is considerable redundancy in many of the
blood–brain transporters.
Long-term neurocognitive deficits are observed in
MSUD, even with acceptable metabolic control (as deter-
mined in blood), and both animal and human data sug-
gests that these deficits correlate with exclusion of the
monoamine precursors TYR and TRP from the brain due
to chronic elevations of BCAAs [1,2,25,33,34]. While our
studies revealed significant effects on brain TYR with diet
Figure 9 Glutamine, aspartate, glutamate and GABA as a function of protein intake and tissue in phenylketonuric (PKU) mice. Two-way
ANOVA, p < 0.05 for tissue, protein intake and interaction. Two-tailed t-test, *p < 0.05 for mutant vs. wild-type. Note: For GABA in CTX, GABA was
also significantly decreased in mutant vs. wild-type mice. In only a single instance did lower protein result in significant correction between
mutant populations (GLN in CB).
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(although we did not quantify monoamine neurotransmit-
ters). Alternatively, our data supports the premise that
long-term neurocognitive deficits in MSUD patients may
also correlate with depletion of amino acid neurotransmit-
ters (ASP, GLU and GABA). Based upon the preliminary
studies in the current report, our next objectives are to
investigate LEU-depleted diets in imsud−/− mice that are
appropriately supplemented with ILE and VAL, a diet cor-
responding to that used in MSUD patients, and to again
investigate the amino acid outcomes both regionally in
brain and blood. Such studies will yield a better overview
of the expected outcomes for a diet more closely resem-
bling that utilized in the clinic. The main conclusions
drawn from the current report include:
 The first detailed cross-correlation assessment of
amino acids in brain and blood, as a function of total
protein intake, and the first analysis of amino acids
in discrete regions of the brain of imsud mice,
including cerebellum, cortex and striata
 A clear demonstration that blood amino acid
analysis, and the assignment of metabolic control
with respect to BCAA levels, represents only a
partial picture of brain amino acid homeostasis
These results further support the concept that dietary
intervention in MSUD is likely to be insufficient to avoid
neurocognitive deficiencies in patients, underscoring the
urgent need for more focused therapeutics in MSUD.
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